Development and Clinical Application of [11C]Verapamil-PET
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The major hypothesis explaining drug resistance is overexpression of p-glycoprotein at the
target lesion. Based on several studies, p-glycoprotein (P-gp) has an important role in
neurologic diseases, especially in drug resistant epilepsy. But there is no surrogate marker
that can quantify the expression of P-gp because of the difficulty in measuring substances in
the neurologic system and the lack of clinical trials. Here, the investigators use a novel
non-invasive [11C] -verapamil Brain PET and SPAM analytic method as a surrogate marker for
quantifying the expression of p-glycoprotein.